Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;10(2):154.
doi: 10.3390/vaccines10020154.

Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination

Affiliations

Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination

Raquel Guiomar et al. Vaccines (Basel). .

Abstract

Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive follow-up studies with distinct vaccines and populations are able to promote robust and reliable data to better understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing (achieved by surrogate ELISA assay) antibodies throughout time, from vaccinated and previously infected (PI) health care workers (HCW) in Portugal. We analyzed serum samples of 132 HCW, who were vaccinated and with previous SARS-CoV-2 infection. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25-70 days (M3) and 150-210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD/S) antibody geometric mean titers found on vaccinated HCW at M2 (GM = 116.1 BAU/mL; CI: 92.3-146.1) were significantly higher than those found on PI HCW at recruitment (M1) (GM = 35.9 BAU/mL; CI:15.4-83.4), and the neutralizing antibodies (nAb) were similar between these groups, of 93.2 UI/mL (95% CI 73.2-118.5) vs. 84.1 UI/mL (95% CI 40.4-155.9), respectively. We detected around 10-fold higher IgG (anti-RBD/S) antibodies titers in M3 when compared with M2, with a slight but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers was correlated with IgG (anti-RBD/S) antibodies titers; however, in contrast to IgG (anti-RBD/S) antibodies titers, we did not detect a decrease in the nAb titer 36 days after a second vaccine dose uptake. At M4, a decrease of 8-fold in binding IgG (anti-RBD/S) and nAb was observed. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD/S) antibodies titers and nAb titers could be correlated, but an ongoing follow up of the cohort is required to better understand this correlation, and the duration of the immune response.

Keywords: COVID-19; health care workers; immunology; neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Concentration of IgG anti-SARS-CoV-2 spike receptor-binding domain (RBD) titers (logarithmic scale 10) reported in the box-whisker plots (and outliers) for individuals with previous infection at M1 and vaccinated individuals without previous infection for the three different moments of observation.
Figure 2
Figure 2
Concentration of neutralizing antibodies (nAb) titers (logarithmic scale 10) reported in the box-whisker plots (and outliers) for individuals with previous infection and vaccinated individuals without previous infection for the four different moments of observation.

Similar articles

Cited by

References

    1. WHO . Evaluation of COVID-19 Vaccine Effectiveness. WHO; Geneva, Switzerland: 2021. p. 70.
    1. Forni G., Mantovani A., Forni G., Mantovani A., Moretta L., Rappuoli R., Rezza G., Bagnasco A., Barsacchi G., Bussolati G., et al. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ. 2021;28:626–639. doi: 10.1038/s41418-020-00720-9. - DOI - PMC - PubMed
    1. Infarmed Infarmed COVID-19 -Vacinas Aprovadas (Quadro Resumo) 2021. [(accessed on 20 October 2021)]. Available online: https://www.infarmed.pt/web/infarmed/vacinas-aprovadas.
    1. Carrillo J., Izquierdo-Useros N., Ávila-Nieto C., Pradenas E., Clotet B., Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem. Biophys. Res. Commun. 2021;538:187–191. doi: 10.1016/j.bbrc.2020.10.108. - DOI - PMC - PubMed
    1. Lombardi A., Bozzi G., Ungaro R., Villa S., Castelli V., Mangioni D., Muscatello A., Gori A., Bandera A. Mini Review Immunological Consequences of Immunization with COVID-19 mRNA Vaccines: Preliminary Results. Front. Immunol. 2021;12:657711. doi: 10.3389/fimmu.2021.657711. - DOI - PMC - PubMed